Sign up to access all valuation multiples
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
1997
173
LTM Revenue $78.9M
LTM EBITDA $41.7M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ChemoMetec has a last 12-month revenue (LTM) of $78.9M and a last 12-month EBITDA of $41.7M.
In the most recent fiscal year, ChemoMetec achieved revenue of $63.4M and an EBITDA of $30.2M.
ChemoMetec expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ChemoMetec valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $78.9M | XXX | $63.4M | XXX | XXX | XXX |
| Gross Profit | $54.6M | XXX | $57.2M | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $41.7M | XXX | $30.2M | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 48% | XXX | XXX | XXX |
| EBIT | $38.4M | XXX | $26.3M | XXX | XXX | XXX |
| EBIT Margin | 49% | XXX | 41% | XXX | XXX | XXX |
| Net Profit | $30.4M | XXX | $21.2M | XXX | XXX | XXX |
| Net Margin | 39% | XXX | 33% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 3, 2025, ChemoMetec's stock price is DKK 514 (or $80).
ChemoMetec has current market cap of DKK 8.9B (or $1.4B), and EV of DKK 8.7B (or $1.4B).
See ChemoMetec trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.4B | XXX | XXX | XXX | XXX | $1.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 3, 2025, ChemoMetec has market cap of $1.4B and EV of $1.4B.
ChemoMetec's trades at 19.2x EV/Revenue multiple, and 38.2x EV/EBITDA.
Equity research analysts estimate ChemoMetec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ChemoMetec has a P/E ratio of 45.7x.
See valuation multiples for ChemoMetec and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 17.1x | XXX | 19.2x | XXX | XXX | XXX |
| EV/EBITDA | 32.4x | XXX | 38.2x | XXX | XXX | XXX |
| EV/EBIT | 35.2x | XXX | 42.5x | XXX | XXX | XXX |
| EV/Gross Profit | 24.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 45.7x | XXX | 54.8x | XXX | XXX | XXX |
| EV/FCF | 60.5x | XXX | 79.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChemoMetec's last 12 month revenue growth is 14%
ChemoMetec's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
ChemoMetec's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ChemoMetec's rule of X is 87% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ChemoMetec and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 50% | XXX | XXX | XXX |
| EBITDA Growth | 16% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 66% | XXX | 64% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 87% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ChemoMetec acquired XXX companies to date.
Last acquisition by ChemoMetec was XXXXXXXX, XXXXX XXXXX XXXXXX . ChemoMetec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was ChemoMetec founded? | ChemoMetec was founded in 1997. |
| Where is ChemoMetec headquartered? | ChemoMetec is headquartered in Denmark. |
| How many employees does ChemoMetec have? | As of today, ChemoMetec has 173 employees. |
| Who is the CEO of ChemoMetec? | ChemoMetec's CEO is Mr. Martin Helbo Behrens. |
| Is ChemoMetec publicy listed? | Yes, ChemoMetec is a public company listed on CSE. |
| What is the stock symbol of ChemoMetec? | ChemoMetec trades under CHEMM ticker. |
| When did ChemoMetec go public? | ChemoMetec went public in 2006. |
| Who are competitors of ChemoMetec? | Similar companies to ChemoMetec include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of ChemoMetec? | ChemoMetec's current market cap is $1.4B |
| What is the current revenue of ChemoMetec? | ChemoMetec's last 12 months revenue is $78.9M. |
| What is the current revenue growth of ChemoMetec? | ChemoMetec revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of ChemoMetec? | Current revenue multiple of ChemoMetec is 17.1x. |
| Is ChemoMetec profitable? | Yes, ChemoMetec is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ChemoMetec? | ChemoMetec's last 12 months EBITDA is $41.7M. |
| What is ChemoMetec's EBITDA margin? | ChemoMetec's last 12 months EBITDA margin is 53%. |
| What is the current EV/EBITDA multiple of ChemoMetec? | Current EBITDA multiple of ChemoMetec is 32.4x. |
| What is the current FCF of ChemoMetec? | ChemoMetec's last 12 months FCF is $22.3M. |
| What is ChemoMetec's FCF margin? | ChemoMetec's last 12 months FCF margin is 28%. |
| What is the current EV/FCF multiple of ChemoMetec? | Current FCF multiple of ChemoMetec is 60.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
